Cite
HARVARD Citation
Morra, D. et al. (2019). Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. British journal of haematology. pp. 232-241. [Online].